EMBOLISM
ISWANTO PRATANU
Introduction
DVT
VTE
PE
Risk Factor
o Immobilization
o Travel of 4 hours or more in the past month
o Surgery within the last 3 months
o Malignancy (17%)
o History thromboplebitis
o Trauma to lower extremities and pelvis during past 3 mos
o Smoking
o Central venous instrumentation within past 3 months
o Stroke
o Prior pulmonary embolism
o Heart failure
o COPD
o Hypercoagulable states (hereditary)
o Hormonal therapy
(Stein 2007) (Ouelette DR 2015)
Pathophysiology
Embolus
Circulation
Chemical factors
Neurohormonals
Pulmonary vascular
obstruction
Vasoconstriction
pulmonary resistance
compliance artery
PE
RV dilatations
Gas exchange
(Goldhaber 2003,
Konstantinides 2014)
Desaturation
CO
RV heart failure
Disturbance
ventilationHypoxemia
perfusion
CARDIOVASCULAR EMERGENCIES COURSE
Diagnosis
Clinical manifestation of PE is not specific
Suspected PE:
Dyspneu
Chest pain
Presyncope or syncope
Haemoptysis (coughing up blood)
Palpitations
Leg swelling and discomfort
(Goldhaber 2003)
(Konstantinides 2014)
Scoring system
(Wells 2000)
Scoring system
Laboratory Test
D-Dimer
Suspected low or
intermediate risk of
PE
ELISA method:
sensitivity 95%
Specificity decreased
almost 10% in >80
years old
(Vyas 2012, Konstantinides 2014)
Laboratory Test
BNP
Increase in about 50% PE patients
Higher sensitivity as indicator in heart failure
Troponin I or T
Increase in PE patients
Imaging Test
Imaging Test
Echocardiography
Detect morphology dan function changes of RV
Prognostic value in unstable haemodynamics
patients is still the best
No sign of RV overload or dysfunction exclude
suspected high risk PE
(Konstantinides 2014)
Thrombus
Thrombus
Thrombus
Thrombus
Imaging Test
CT Angiography
Standart imaging for
patient with
suspected PE
Adequate imaging
pulmonary vascular
to segmental level
MDCT giving
imaging of thrombus
in pulmonary
vascular, detect RV
dilatation and RV
dysfunction
(Lucassen 2013, Konstantinides 2014)
(Konstantinides 2014)
(Konstantinides 2014)
Therapy
Haemodynamic and Respiratory Support
Supportive treatment is vital acute RV failure
low systemic output cause of death
Modest (500 ml) fluid challenge help increase
cardiac index
Vasopresor is often necessary
NE improves RV function via direct positive inotropic
effect
Dobutamine or dopamine considered for patient with
low cardiac index and normal BP
(Konstantinides 2014)
Therapy
Anticoagulation
Recommended to
prevent early death and
recurrent symptomatic
or fatal VTE
Standard duration at
least 3 months
Acute phase treatment
consist of parenteral
UFH, LMWH or
fondaparinux over first
5-10 days
(Quinlan 2004, Buller2012)
Therapy -- Thrombolysis
Therapy
Systemic thrombolysis is not routinely
recommended as primary treatment for patients
with intermediate-high risk PE, but should be
considered if clinical signs of haemodynamic
decompensation appear
Percutaneous catheter-directed treatment or
surgical pulmonary embolectomy are
alternative rescue procedures for intermediatehigh risk PE
(Konstatinides 2012, Lavorini 2013)
Prognostic
(Jimenez 2010)
Prognostic
Summary
PE has high morbidity and mortality
The diagnose of PE is difficult to determine
because remain asymptomatic
Risk stratification need to be done for
suspected PE to determine diagnosis and
therapy
With prompt diagnosis and management,
recurrent PE and mortality could be prevented
CARDIOVASCULAR EMERGENCIES COURSE
THANK YOU